2020 14:28 | Wednesday
GENEVA BIOTECH CO-FOUNDERS PUBLISH IN SCIENCE GOOD REVIEW IN FORBES
Press Release on Geneva Biotech’s COVID-19 research
Published in Science using MultiBac: the structure of the human histone pre-mRNA 3′-end processing machinery
Published in Nature using MultiBac, the structure of the inner kinetochore CCAN complex assembled onto a centromeric nucleosome
Geneva Biotech releases information for the first time on their drug discovery pipeline. See Pipeline
Published in Nature using MultiBac, the structure of the influenza A virus RNA polymerase gives insight into flu virus replication
Geneva Biotech releases the first efficient non-lentiviral transduction system for immortal T-cells and B-cells. Please see Mammalian Product Category “T-Cells B-Cells”
Replication fork protection by BRCA1–BARD1 revealed in Nature
The cryo-EM structure of Pan2-Pan3 in complex with a poly(A) RNP published in Cell provides molecular insights into the process of poly(A) tail shortening
BRISC–SHMT2 interactions are key to immune regulation as revealed in Nature
Many of Geneva Biotech’s industry leading baculoviral genomes are now available as competent cells in Europe, Asia, and North America !
Structure and regulation of key chromatin remodelling enzyme INO80 revealed in Nature
Protein-Protein interactions (PPIs) are central to most essential cellular mechanisms including gene expression, protein translocation, cell cycle progression and signal transduction. Bellón-Echeverría et al. published in Scientific Reports a proof of concept employing MultiBacMam to identify new small-molecule inhibitors of the CDK5-p25 protein-protein interaction. The method is generally applicable to any multiprotein cascade important in drug discovery.
Stolt-Bergner et al. published in Journal of Structural Biology a benchmarking initiative in 13 independent labs to compare the world’s leading baculovirus expression systems. Geneva Biotech’s EMBacY virus was ranked #1 in performance.
Tchesnokov et al. published in Scientific Reports a production system for Ebola Virus RNA-Dependent RNA Polymerase Complex using the MultiBac system, providing a powerful discovery system for this key drug target.
Geneva Biotech and Sphere Fluidics launch R&D project to develop methods that enable large DNA cargo delivery and genome engineering in primary cells that have proven refractory to traditional transfection, electroporation, or transduction methods. LINK
Geneva Biotech and partners have recorded >70% increase in baculovirus DNA stability in scale up experiments to 100L using second generation SynBac genomes. DNA stability was found to strongly correlate (r = 0.91) with expression yield of multiple different test proteins.
Intact Genomics is a world leader of ultra-high competent cell production and BAC (bacterial artificial chromosome) library related technologies. Intact has partnered with Geneva Biotech to offer North American customers competent cells containing Geneva Biotech’s viral genomes. See their Geneva Biotech partnered products here INTACT GENOMICS
The Ban lab published in Science the structure of key drug target mTORC1 using the MultiBac system, providing critical information on the function and intricate regulation of this important enzyme which is implicated in common human diseases including cancer and diabetes.
Developed by the European Union ComplexINC R&D consortium, Kinase Factory™ is a baculovirus expression system where entire 5-8 protein chaperone machineries specific for protein kinase folding were integrated into synthetic baculovirus genomes to provide a unique platform for production of kinases that display poor folding or stability. The system is also ideal for boosting production yields of kinases for large scale expression, e.g. for target production for drug discovery.
Developed by the European Union ComplexINC R&D consortium, Hormone Receptor Factory™ is a baculovirus expression system where entire 5-7 protein chaperone machineries specific for hormone folding were integrated into synthetic baculovirus genomes to provide a unique platform for production of hormone receptors that display poor folding or stability. The system is also ideal for boosting production yields of hormone receptors for large scale expression, e.g. for target production for drug discovery.
Developed at the European Molecular Biology Laboratory (EMBL), ComplexLink™ is a system of polyprotein production combined with co-production of sequence-specific proteases that co-translationally cleave the polyprotein into functional monomeric subunits. The technology provides unique advantages over existing expression systems for production of multiprotein complexes where subunit stoichiometry is difficult to control. The technology was applied to produce recombinant influenza polymerase complex from a self-processing polyprotein, as recently published in Nature.
The European Molecular Biology Laboratory (EMBL), Europe's flagship laboratory for basic research in molecular biology, has granted Geneva Biotech an exclusive license for intellectual property covering minimal baculoviral genomes. These genomes were created using modern synthetic biology techniques, and will appear in future as products "SynBac".
The Swiss Commission for Technology and Innovation (CTI) awards Geneva Biotech and Partner University of Geneva CHF 977k for development of an early stage drug discovery program in cellular signaling.
The influenza polymerase remained inaccessible for decades – the challenge to produce this highly complicated protein complex for detailed analysis, proved to be a seemingly insurmountable technical challenge. The break-through studies, lead by Stephen Cusack, renowned influenza expert and Head of the EMBL Grenoble Outstation, used Geneva Biotech's ComplexLinkTM technology to produce recombinant influenza polymerase complex from a self-processing polyprotein, as recently published in Nature.
Geneva Biotech has launched a subsidiary in Indianapolis, Indiana to provide better services to our US-based clients.
Membrane proteins constitute a large and important fraction of the proteome, with 80% of the druggable targets in cells being membrane proteins. The holotranslocon, a large transmembrane multiprotein complex comprising seven subunits catalyzes the entry of proteins into cell membranes. EMBL and UK based scientists used the MultiColi™ expression system in the ComplexINC R&D consortium to engineer a tightly regulated multigene co-expression circuit which enabled the functional assembly of holotranslocon complex published in the early edition of the Proceedings of the National Academy USA.
Geneva Biotech joins the SynSignal R&D consortium for development of the next generation of synthetic biology tools and technologies.
VLP Factory™ constitutively secretes promiscuous virus matrix proteins, with built in functionality to allow you to introduce multiple additional expression cassettes for production of multiprotein VLPs.
Developed as a variant of our transient mammalian multiprotein expression system, MultiMam Stable™ allows for easy DNA recombination-based assembly of multiprotein expression cassettes, followed by chromosomal integration and copy number expansion.
Developed through a collaboration between the University of Vienna and the European Molecular Biology Laboratory (EMBL), SweetBac™ is the world’s first baculovirus that produces humanized glycosylation patterns on recombinantly expressed proteins. SweetBac™ provides unique advantages over existing baculovirus expression systems for i) production of targets for drug discovery and assay development ii) antibody development against membrane proteins like GPCRs and ion channels, and iii) manufacturing of biologics in insect cells with humanized glycosylation patterns.
The Berger Laboratory from EMBL Grenoble have described in molecular detail the architecture of the central scaffold of TFIID: the human protein complex essential for transcription from DNA to mRNA. The study, published today in Nature, opens new perspectives in the study of transcription and of the structure and mechanism of other large multi-protein assemblies involved in gene regulation. MultiBac™ has now been used in more than a dozen Nature and Science publications in the last 3 years.
The European Molecular Biology Laboratory (EMBL), Europe's flagship laboratory for basic research in molecular biology, has granted Geneva Biotech an exclusive license for intellectual property covering a portfolio of protein expression technologies. The company has also concluded a research collaboration agreement with EMBL.